pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,349 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1817Endpoints1411Fierce Biotech731BioSpace719BioPharma Dive532raps241onclive165fda recalls116
therapy area
allOncology12513Rare Disease3255Immunology2927Cardiology2830Hematology2218Pulmonology2176Vaccines
  • Newly elected doctors and scientists aim to rebuild public trust in science after midterm wins
    Last week doctors and scientists across the United States were elected to office, with the help of the group 314 Action. The organization, which supports Democratic candidates with scientific backg…
    STAT · 2d agoNeutral↗ source
  • Webinar Highlights Benefits of Cryopreserved Cells for Faster, Consistent CAR-T Manufacturing
    The webinar, scheduled for November 12, 2026, discusses how the timing of immune-cell isolation and the use of cryopreserved starting materials affect cell-therapy manufacturing. It focuses on both…
    BioSpace · 1d agoNeutral↗ source
← prev
page 3 of 134
next →
fda medwatch112
globenewswire health73
fda press59
1820
Psychiatry & CNS1221
Ophthalmology1081
Endocrinology & Metabolism785
Pain784
Nephrology764
Biopharma hiring surge in New Jersey as BioSpace lists ~300 open positions across 10 companies
BioSpace job postings in New Jersey increased year over year in October 2026, with around 300 positions now listed. While postings fell 25% from September to October, overall year-over-year number…
BioSpace · 2d agoNeutral↗ source
  • Study finds Black Americans share many concerns with MAHA despite low overall support
    Jerel Ezell, an epidemiologist at the University of Chicago Medical Center, writes an opinion piece examining the complex relationship between the MAHA movement and Black Americans. A 2025 poll by…
    STAT · 2d agoNeutral↗ source
  • Blackstone bets $1.5B on Pfizer’s obesity drug
    The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.
    BioPharma Dive · 1d ago↗ source
  • Experts update prostate cancer screening guidelines for men
    Are you an American man between 50 and 69? You might want to get checked for prostate cancer, ACS says in reversal of previous guidelines.
    STAT · 2d ago↗ source
  • Novartis' Zolgensma linked to tumors as FDA probes gene therapy and orders GLP-1 eye risk warnings
    Novartis confirmed that nine patients who received its Zolgensma gene therapy for spinal muscular atrophy have developed tumors, prompting the FDA to open an investigation into the approved treatme…
    BioSpace · 3d agoRegulatoryNegative↗ source
  • China’s five-year plan positions it to become a global leader in innovative biopharma by 2030
    China’s latest five‑year plan sets an ambitious target to turn the country into a major source of innovative medicines for the world market. Experts cited by BioSpace say the goal is within reach,…
    BioSpace · 3d agoRegulatoryPositive↗ source
  • Study of 100,000 diverse Americans uncovers thousands of new drug-response genetic variants
    A new analysis of data from the NIH All of Us program examined nearly 100,000 participants from a wide range of ancestries. Researchers identified thousands of previously unknown genetic variants i…
    STAT · 2d agoPositive↗ source
  • U.S. 'most-favored nations' policy prompts drugmakers to reconsider overseas launches
    The White House's "most-favored nations" rule, which would tie foreign drug prices to U.S. prices, is causing U.S. pharma firms to rethink launching products abroad. Companies are exploring strate…
    STAT · 2d agoRegulatoryNeutral↗ source
  • Senate Health Committee Schedules Vote on FDA Commissioner Nominee Heidi Overton
    Senate health committee set a vote for November 18 on President Trump's nominee Heidi Overton to become FDA commissioner. The outcome will determine whether the nomination proceeds to the full Sen…
    STAT · 3d agoRegulatoryNeutral↗ source
  • Capricor boosts manufacturing capacity as FDA decision on DMD cell therapy looms
    Capricor Therapeutics, a biotech developing a cell therapy for Duchenne muscular dystrophy, is preparing for an FDA decision expected by late November. The company’s third-quarter operating expens…
    BioSpace · 3d agoRegulatoryNeutral↗ source
  • Study warns German drug price hikes could raise US Medicaid spending by $300 million
    A new Harvard Medical School study examined the effect of Germany's drug price increases on the United States under President Trump's most‑favored‑nation policy, which ties US federal drug pricing…
    BioPharma Dive · 2d agoNegative↗ source
  • Study proposes new obesity metric that could reverse diagnoses for millions, aiming for more precise care
    Researchers published a study in Nature that suggests an alternative way to define obesity could change the diagnosis status for millions of people. The proposed framework separates pre-clinical an…
    STAT · 2d agoNeutral↗ source
  • PepGen stock surges as DM1 oligonucleotide PGN-EDODM1 shows record splicing correction in Phase 2
    PepGen reported that its experimental oligonucleotide PGN-EDODM1 achieved a mean splicing correction of 46.5% at week 13 in a Phase 2 trial for myotonic dystrophy type 1 (DM1). This performance exc…
    BioSpace · 2d agoPositive readoutPositive↗ source
  • Incoming Democratic committee chairs move to probe Trump-era most-favored-nation drug pricing deals
    The column notes that the newly appointed Democratic chairs of key congressional committees are planning to examine the most-favored-nation (MFN) drug pricing agreements that were negotiated during…
    STAT · 3d agoRegulatoryNeutral↗ source
  • AstraZeneca acquires Omniose to boost conjugate vaccine platform as FDA flags vision-loss risk for GLP-1 drugs
    AstraZeneca announced it has acquired vaccine startup Omniose, though the financial terms were not disclosed. The purchase gives AstraZeneca access to Omniose's bioconjugation technology, a method…
    BioPharma Dive · 3d agoDealNeutral↗ source
  • U.S. faces possible loss of measles elimination status as WHO panel convenes
    A WHO regional committee will meet for four days to decide if the United States still meets criteria for measles elimination. Current indicators suggest the country may no longer qualify, raising…
    STAT · 3d agoRegulatoryNegative↗ source
  • Federal panel overseeing preventive care receives blanket ethics waivers despite members' pharma and practice conflicts
    Federal officials granted blanket ethics waivers to every member of the U.S. Preventive Services Task Force, allowing them to serve despite clear financial conflicts of interest. Documents show so…
    STAT · 3d agoRegulatoryNegative↗ source
  • US biotech faces growth slowdown as China’s coordinated investment threatens industry
    During a BioSpace webinar, industry experts warned that uncertainty in U.S. policy is slowing biotech growth while China accelerates its life-science sector with deliberate investment. Strand Ther…
    BioSpace · 3d agoRegulatoryNegative↗ source
  • FDA issues warning letters to two Chinese API makers for refusing record requests
    The U.S. Food and Drug Administration sent warning letters to Chongqing Qiancan Technology and Tianjin Healthcare Medical Technology after both companies declined to provide records the agency requ…
    BioSpace · 2d agoRegulatoryNegative↗ source
  • Capricor trims 10% of workforce as FDA decision on Duchenne cell therapy approaches
    Capricor Therapeutics announced it is cutting about 10% of its staff ahead of an upcoming FDA decision on its Duchenne muscular dystrophy cell therapy, deramiocel. The biotech said it had 231 full…
    BioSpace · 2d agoLayoffsNegative↗ source
  • MDCalc unveils CrossCover to boost clinician confidence in AI chatbot answers while protecting privacy
    MDCalc, a medical reference website, announced a new tool called CrossCover. CrossCover is designed to check clinicians' queries for privacy issues and evaluate AI chatbot responses for accuracy,…
    STAT · 3d agoPositive↗ source
  • Former ER doctor argues that limiting data input can improve clinical AI tools
    Graham Walker, a former emergency‑room physician and co‑founder of MDCalc, was interviewed for STAT’s AI Prognosis newsletter about his new AI tool. Walker explains that giving AI systems only the…
    STAT · 2d agoNeutral↗ source
  • BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026
    BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…
    BioSpace · 3d agoNeutral↗ source